# Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Source: https://onco.cc/trials/nct00742027/  
OnCo record `nct00742027` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Panobinostat in Hodgkin lymphoma, run by Novartis Pharmaceuticals, completed.

## Summary

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT00742027 by Novartis Pharmaceuticals, with 129 participants recorded, started 2008-09-16 and reaching its primary completion in 2013-08-12. Interventions recorded: Panobinostat. Conditions recorded: Classical Hodgkin's Lymphoma.

Linked to the drug Panobinostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00742027
- Phase: 2
- Setting: A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkins Lymphoma After High-dose Chemotherapy With Autologous Stem Cell Transplant
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 129

## Sources

- ClinicalTrials.gov NCT00742027: https://clinicaltrials.gov/study/NCT00742027

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- drugs: [Panobinostat](https://onco.cc/drugs/panobinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct00742027.json